Price$98.67+1.98 (+2.05%)
2026-03-052026-06-08
News · 26 weeks53-87%
2025-12-142026-06-07
Mix2590d
- Insider12(48%)
- SEC Filings5(20%)
- Other3(12%)
- Earnings2(8%)
- Analyst2(8%)
- Dividends1(4%)
Latest news
25 items- ANALYSTWolfe Research resumed coverage on RevvityWolfe Research resumed coverage of Revvity with a rating of Peer Perform
- SECSEC Form SD filed by Revvity Inc.SD - REVVITY, INC. (0000031791) (Filer)
- SECSEC Form 10-Q filed by Revvity Inc.10-Q - REVVITY, INC. (0000031791) (Filer)
- INSIDERDirector Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)4 - REVVITY, INC. (0000031791) (Issuer)
- INSIDERDirector Vandebroek Sophie V. was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)4 - REVVITY, INC. (0000031791) (Issuer)
- INSIDERDirector Michas Alexis P was granted 2,684 shares, increasing direct ownership by 4% to 63,767 units (SEC Form 4)4 - REVVITY, INC. (0000031791) (Issuer)
- INSIDERDirector Witney Frank was granted 2,280 shares, increasing direct ownership by 11% to 23,354 units (SEC Form 4)4 - REVVITY, INC. (0000031791) (Issuer)
- INSIDERDirector Witz Pascale was granted 2,280 shares, increasing direct ownership by 17% to 15,985 units (SEC Form 4)4 - REVVITY, INC. (0000031791) (Issuer)
- INSIDERDirector Barrett Peter was granted 2,280 shares, increasing direct ownership by 9% to 28,293 units (SEC Form 4)4 - REVVITY, INC. (0000031791) (Issuer)
- INSIDERDirector Mcmurry-Heath Michelle was granted 2,280 shares, increasing direct ownership by 54% to 6,513 units (SEC Form 4)4 - REVVITY, INC. (0000031791) (Issuer)
- INSIDERDirector Chapin Samuel R. was granted 2,280 shares, increasing direct ownership by 11% to 22,676 units (SEC Form 4)4 - REVVITY, INC. (0000031791) (Issuer)
- INSIDERDirector Vounatsos Michel was granted 2,280 shares, increasing direct ownership by 19% to 13,977 units (SEC Form 4)4 - REVVITY, INC. (0000031791) (Issuer)
- SECRevvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - REVVITY, INC. (0000031791) (Filer)
- PRRevvity Announces Financial Results for the First Quarter of 2026Revenue of $711 million; pro forma revenue of $687 million; 7% revenue growth; 3% organic growth; 6% pro forma organic growth GAAP EPS from continuing operations of $0.37; adjusted EPS from continuing operations of $1.06; GAAP pro forma EPS from continuing operations of $0.40; pro forma adjusted EPS from continuing operations of $1.04 Announces intention to divest China Immunodiagnostics business Updates full year 2026 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended April 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.37, as compared to $0.35 in the same period a year ago. Revenue for the
- SECSEC Form 8-K filed by Revvity Inc.8-K - REVVITY, INC. (0000031791) (Filer)
- PRRevvity Board Declares Quarterly DividendThe Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 7, 2026 to all shareholders of record at the close of business on July 17, 2026. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screeni
- INSIDERSEC Form 4 filed by Gonzales Anita4 - REVVITY, INC. (0000031791) (Issuer)
- PRRevvity to Present at Upcoming Investor ConferencesRevvity, Inc. (NYSE:RVTY), today announced it will present at the following investor conferences: BofA Securities 2026 Health Care Conference Wednesday, May 13, 2026 9:20 a.m. PT - Steve Willoughby, senior vice president, investor relations, ESG, risk Goldman Sachs 47th Annual Global Healthcare Conference Tuesday, June 9, 2026 8:40 a.m. ET - Prahlad Singh, president and chief executive officer Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be available on the Events section of the Company's website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and w
- ANALYSTRevvity downgraded by Barclays with a new price targetBarclays downgraded Revvity from Overweight to Equal Weight and set a new price target of $95.00
- PRRevvity to Hold Earnings Call on Tuesday, May 5, 2026Revvity, Inc. (NYSE:RVTY), today announced that it will release its first quarter 2026 financial results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows
- PRRevvity Unveils its Signals BioDesign Offering to Advance Biologic Research WorkflowsScalable collaboration for biotech and pharma teams: Enables high-throughput construct design (up to 1,000 constructs) with real-time data sharing Integrated, AI-ready biologics ecosystem: Connects design to execution through native Signals One platform integration and cloud-native infrastructure Unified molecular cloning workflows: Supports Golden Gate, Gibson assembly, restriction/ligation, primer design, and sequencing analysis in one platform Revvity, Inc. (NYSE:RVTY) announced that its Revvity Signals Software business is launching Signals BioDesignTM, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for biotech and pharma R&D tea
- INSIDERSEC Form 4 filed by Gonzales Anita4 - REVVITY, INC. (0000031791) (Issuer)
- SECSEC Form DEFA14A filed by Revvity Inc.DEFA14A - REVVITY, INC. (0000031791) (Filer)
- SECSEC Form DEF 14A filed by Revvity Inc.DEF 14A - REVVITY, INC. (0000031791) (Filer)
- INSIDEROfficer Gonzales Anita was granted 1,721 shares, increasing direct ownership by 42% to 5,799 units (SEC Form 4)4 - REVVITY, INC. (0000031791) (Issuer)
RVTY FAQ
5 questionsWhere does RVTY stock trade?
Revvity Inc. (RVTY) is listed on NYSE.What sector and industry is RVTY in?
Revvity Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.What are analysts saying about RVTY?
Revvity Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-06-02.What companies are similar to RVTY?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), BRKR (Bruker Corporation). Compare RVTY side-by-side with any of them on Quantisnow.How can I track RVTY on Quantisnow?
Quantisnow aggregates Revvity Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RVTY to receive live email and push alerts on every new disclosure.